Phenotypes Associated with This Genotype

Genotype
MGI:4439300

• Allelic Composition: Tg(CAG-lacZ,-SV40)#Bcv/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:158388 )

• recombinant adenoviruses Ad5CMVeGFP (AdGFP) or Ad5CMVCre (AdCre) are delivered to the ovarian surface epithelium (OSE) in vivo via intrabursal injection

• with a median survival of 113 days after injection

• decreased survival time in mice treated with exogenous 17beta-estradiol (E2) (50 vs. 113 days after AdCre)

neoplasm

increased metastatic potential ( J:158388 )

• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment

abnormal tumor morphology ( J:158388 )

• tumors from P4 treatment have a more diffuse pattern and a higher incidence of zellballen

• tumors from E2-treated mice display a more diffuse appearance, abundant surface papillae, and large areas of necrosis

abnormal tumor susceptibility ( J:158388 )

• E2 treatment accelerates tumor onset

• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment

abnormal tumor incidence ( J:158388 )

increased pancreas tumor incidence ( J:158388 )

• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

increased ovary tumor incidence ( J:158388 )

♀ • mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase

♀ • tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations

increased ovarian carcinoma incidence ( J:158388 )

♀ • nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8)

♀ • frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct

increased liver tumor incidence ( J:158388 )

• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

increased spleen neoplasm incidence ( J:158388 )

• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

decreased tumor incidence ( J:158388 )

• decreased incidence of ovarian neoplasms (64 vs. 82% in controls) in progesterone (P4)-treated mice (n=11)

homeostasis/metabolism

ascites ( J:158388 )

• peritoneal ascites with volumes ranging from 0.5-7.5 ml in 64% of the mice

• accumulation of ascites and adhesions in the abdomen in one mouse without ovarian tumor (out of 11 mice)

• E2 treatment decrease the incidence of peritoneal ascites accumulation

muscle

abnormal diaphragm morphology ( J:158388 )

• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

endocrine/exocrine glands

increased pancreas tumor incidence ( J:158388 )

• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

increased ovary tumor incidence ( J:158388 )

♀ • mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase

♀ • tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations

increased ovarian carcinoma incidence ( J:158388 )

♀ • nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8)

♀ • frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct

reproductive system

increased ovary tumor incidence ( J:158388 )

♀ • mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase

♀ • tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations

increased ovarian carcinoma incidence ( J:158388 )

♀ • nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8)

♀ • frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct

liver/biliary system

increased liver tumor incidence ( J:158388 )

• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
ovarian cancer		DOID:2394	OMIM:167000 OMIM:607893	J:158388